"Sulfonamides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of compounds that contain the structure SO2NH2.
| Descriptor ID |
D013449
|
| MeSH Number(s) |
D02.065.884 D02.886.590.700
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Sulfonamides".
Below are MeSH descriptors whose meaning is more specific than "Sulfonamides".
This graph shows the total number of publications written about "Sulfonamides" by people in this website by year, and whether "Sulfonamides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 1999 | 2 | 2 | 4 |
| 2000 | 1 | 2 | 3 |
| 2002 | 6 | 1 | 7 |
| 2003 | 4 | 1 | 5 |
| 2004 | 1 | 4 | 5 |
| 2005 | 1 | 5 | 6 |
| 2006 | 6 | 3 | 9 |
| 2007 | 4 | 2 | 6 |
| 2008 | 7 | 8 | 15 |
| 2009 | 4 | 1 | 5 |
| 2010 | 4 | 3 | 7 |
| 2011 | 8 | 5 | 13 |
| 2012 | 1 | 5 | 6 |
| 2013 | 6 | 3 | 9 |
| 2014 | 10 | 8 | 18 |
| 2015 | 8 | 3 | 11 |
| 2016 | 7 | 2 | 9 |
| 2017 | 7 | 2 | 9 |
| 2018 | 9 | 5 | 14 |
| 2019 | 3 | 5 | 8 |
| 2020 | 7 | 3 | 10 |
| 2021 | 4 | 3 | 7 |
| 2022 | 2 | 2 | 4 |
| 2023 | 1 | 3 | 4 |
| 2024 | 5 | 2 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sulfonamides" by people in Profiles.
-
Antileukemia efficacy of the dual BCL2/BCL-XL inhibitor AZD0466 in acute lymphoblastic leukemia preclinical models. Blood Adv. 2025 Feb 11; 9(3):473-487.
-
Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia. Blood Adv. 2025 Feb 11; 9(3):617-626.
-
Venetoclax-Based Combination Regimens in Acute Myeloid Leukemia. Blood Cancer Discov. 2025 Jan 08; 6(1):23-37.
-
FT538, iPSC-derived NK cells, enhance AML cell killing when combined with chemotherapy. J Cell Mol Med. 2025 Jan; 29(1):e70169.
-
LP-118 is a novel B-cell lymphoma 2 / extra-large inhibitor that demonstrates efficacy in models of venetoclaxresistant chronic lymphocytic leukemia. Haematologica. 2025 Jan 01; 110(1):78-91.
-
An inflammatory state defines a high-risk T-lineage acute lymphoblastic leukemia subgroup. Sci Transl Med. 2025 Jan; 17(779):eadr2012.
-
Effects of amoxicillin dosage on cure rate, gut microbiota, and?antibiotic resistome in vonoprazan and amoxicillin dual therapy for Helicobacter pylori: a multicentre, open-label, non-inferiority randomised controlled trial. Lancet Microbe. 2025 Mar; 6(3):100975.
-
Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax?+?Hypomethylating Agent. Am J Hematol. 2025 Feb; 100(2):260-271.
-
Mutation- and MRD-informed treatments for transplant-ineligible patients. Hematology Am Soc Hematol Educ Program. 2024 12 06; 2024(1):168-177.
-
A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort. Blood. 2024 Nov 28; 144(22):2360-2363.